Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis
Open Access
- 27 April 2014
- journal article
- Published by Springer Science and Business Media LLC in BMC Health Services Research
- Vol. 14 (1), 189
- https://doi.org/10.1186/1472-6963-14-189
Abstract
To examine duration of daily filgrastim prophylaxis, and risk and consequences of chemotherapy-induced neutropenic complications (CINC) requiring inpatient care.This publication has 30 references indexed in Scilit:
- A Way Forward on the Medically Appropriate Use of White Cell Growth FactorsJournal of Clinical Oncology, 2012
- Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practiceBreast Cancer Research and Treatment, 2012
- Effect of Primary Prophylactic Granulocyte-Colony Stimulating Factor Use on Incidence of Neutropenia Hospitalizations for Elderly Early-stage Breast Cancer Patients Receiving ChemotherapyMedical Care, 2011
- Risk of mortality in patients with cancer who experience febrile neutropeniaCancer, 2010
- Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective studyCurrent Medical Research and Opinion, 2010
- Elderly Cancer Patients Receiving Chemotherapy Benefit from First-Cycle PegfilgrastimThe Oncologist, 2007
- 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice GuidelineJournal of Clinical Oncology, 2006
- Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapyCancer, 2005
- Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community PracticesJournal of Clinical Oncology, 2003
- Quality of well-being in older people with osteoarthritisArthritis & Rheumatism, 2003